ArticleTranslational cancer research2025
Exploration of signature-related FAM genes and correlation between FAM50A expression and the pathogenesis and prognosis of hepatocellular carcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) ranks among the deadliest malignancies worldwide, with limited therapeutic options and poor prognosis for advanced-stage patients. The family with sequence similarity (FAM) genes are expected to be potential regulators in tumorigenesis, but their roles in HCC remain poorly understood. This study aimed to systematically investigate the expression profiles and functional roles of FAM genes in HCC. Methods: We leveraged multiple databases, including The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), International Cancer Genome Consortium (ICGC), Gene Expression Omnibus (GEO), Human Protein Atlas (HPA), and Clinical Proteomic Tumor Analysis Consortium (CPTAC), to assess the expression patterns, prognostic implications, DNA methylation, genomic alterations, and associated tumor immune microenvironments of FAM genes. Differentially expressed genes were pinpointed using the DESeq2 package. Least absolute shrinkage and selection operator (LASSO) Cox regression and a nomogram model were employed to identify prognostic FAM genes and estimate the survival outcomes for HCC patients. We performed tissue microarrays and immunohistochemistry on samples from 48 HCC patients to evaluate Results: Five overexpressed and signature-related FAM genes ( Conclusions: This study identifies five FAM genes with prognostic relevance in HCC, among which FAM50A emerges as a potential independent prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.